Naser Jawad Kadhim 1, Dhifaf Zaki Aziz 1, Maysaa Adil Hadi 2
Abstract
DNA topoisomerases are ubiquitous, enzymes needed to control topological problems encountered during DNA replication, transcription, recombination and maintenance of genomic stability. They proved to be valuable targets for cancer chemotherapy. The seeds alkaloids extract of Rue plant (Peganum harmala L. Zygophyllaceae) were fractioned by high performance liquid chromatography as a suitable technique, HPLC waters company, gradient, Nova-Pak, C18*, 4µm, 3.9x150mm, mobile phase ACN-water pH10.7. Thirty-four separate solution depending on the retention time of eluents. The aim of this study is to investigate the trace compounds relatively and used as inhibitors for the topoisomerase II enzyme, the study the poison and suppressor model inhibitions and the synergy and antagonism activity of fractions. The visicinone, harmine, visicine and harmaline, were (2.86, 0.75, 13.14, and 16.62 mg/100mg of plant powder. The harmine ˃vicicinone˃ harmaline˃ vicicine as enzyme inhibitors. The unknown trace compounds gave the best inhibition relatively, the alkaloid fractions gave higher inhibitory units of fraction effective (FE). Results of seeds alkaloid fractions showed that the FE in state of fraction mixture was 36% inhibitory units, while summation of FE of each fraction alone gave higher level than their mixture, where sum of FE of them was 1229% inhibitory units. The suppressor inhibition model according to highest percent of the remain supercoiled DNA plasmid than production of linear and open nicked circular with high value in F8 (84%), the poisons inhibition model activity according to the highest percent of linear and nicked open circular DNA plasmid with high level in F31 (88%). There are a trace compounds within some fraction but that the effectiveness of inhibitory relatively higher than known compounds (harmine, vicisinone, harmaline, and vicisine), this can be purified and used as somewhat better inhibitors. There is antagonism activity among seed alkaloids fractions. The all fractions showed a poison and a suppressor model inhibition action in varies percentage, the suppressor inhibition appear in high value in F8 (84%), while the poisons inhibition model gave high level in F31 (88%).
Keywords: P. harmala; Poison and Suppressor inhibition; Side effect; Tumor target
Copyright © 2016 by The American Society for BioMedicine and BM-Publisher, Inc.
References
1. Hande KR. Topoisomerase II inhibitors. Update on cancer therapeutics 2008;3:13-26. [Abstract/Full-Text]
2. Kellner U, Sehested M, Jensen PB, Gieseler F, Rudolph P. Culprit and victim. DNA topoisomerase II. Lancet Oncol 2002;3:235-43. [PubMed]
3. Sakarkar D, Deshmukh V. Ethnopharmacological Review of Traditional Medicinal Plants for Anticancer Activity. International Journal of PharmTech Research, CODEN (USA) 2011;3(1):298-308. [Abstract/Full-Text]
4. Ferlay J, Shin R, Bray F, Forman D, Mathers C, Parkin M. Estimates of worldwide burden of cancer in Globocan 2008. Int. J. Cancer 2010;127(12):2893-2917. [PubMed]
5. Cassileth B, Deng G. Complementary and alternative therapies for cancer. Oncologist 2004;9(1):80-89. [Abstract/Full-Text]
6. Pommier Y. Reviews Topoisomerase I inhibitors: Camptothecin and beyond. Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, Nature Publishing Group 2006;6:20892-4255.
7. Sobhani M, Ebrahimi A, Mahmoudian M. An in vitro evaluation of human DNA topoisomerase I inhibition by Peganum harmala L. seeds extract and its beta-carboline alkaloids. J. Pharm. Pharmaceut. Sci 2002;5:19-23. [PubMed]
8. Moloudizargari M, Mikaili P, Aghajanshakeri S, Hossein Asghari M, Shayegh J. Pharmacological and therapeutic effects of Peganum harmala and its main alkaloids. Pharmacogn Rev 2013;7(14):199–212. [PubMed]
9. Baikar S, Malpathak N. Secondary metabolites as DNA topoisomerase inhibitors: A new era towards designing of anticancer drugs. Pharmacognosy Reviews 2010;4(7). [PubMed]
10. Boik JC, Newman RA, A Classication Model to Predict Synergism/Antagonism of Cytotoxic Mixtures Using Protein-Drug Docking Scores. BMC Pharmacology 2008;8:13. [PubMed]
11. Boik JC, Newman RA, Boik RJ. Quantifying Synergism/Antagonism Using Nonlinear Mixed-E;;ects Modeling: A Simulation Study.” Statistics in Medicine, 2008; 27(7), 1040-1061. [PubMed]
12. Chen Q, Chao R, Chen H, et al. Antitumor and neurotoxic effects of novel harmine derivatives and structureactivity relationship analysis. Int J Cancer 2005;114:675-82. [PubMed]
13. Nafisi S, Malekabady ZM, Khalilzadeh MA. Interaction of βcarboline alkaloids with RNA. DNA Cell Biol 2010;29:753-61. [PubMed]
14. Li Y, Liang F, Jiang W, et al. DH334, a betacarboline anticancer drug, inhibits the CDK activity of budding yeast. Cancer Biol Ther 2007;6:1193-9. [PubMed]
15. Jiménez J, RiverónNegrete L, Abdullaev F, EspinosaAguirre J, RodríguezArnaiz R. Cytotoxicity of the betacarboline alkaloids harmine and harmaline in human cell assays in vitro. Exp Toxicol Pathol 2008;60:381-9. [PubMed]
16. Zaker F, Oody A, Arjmand A. A study on the antitumoral and differentiation effects of Peganum harmala derivatives in combination with ATRA on leukaemic cells. Arch. Pharm. Res 2007;30(7):844-849. [PubMed]
17. El Gendy MA, Soshilov AA, Denison MS, ElKadi AO. Harmaline and harmalol inhibit the carcinogenactivating enzyme CYP1A1 via transcriptional and posttranslational mechanisms. Food Chem Toxicol 2012;50:353-62. [PubMed]
18. Cao R, Peng W, Chen H, et al. DNA binding properties of 9substituted Harmine derivatives. Biochem Biophys Res Commun 2005;338:1557-63. [PubMed]
19. Sobhani AM, Ebrahimi SA, Mahmoudian M. An in vitro evaluation of human DNA topoisomerase I inhibition by Peganum harmala L. seeds extract and its betacarboline alkaloids. J Pharm Pharm Sci 2002;5:19-23. [PubMed]
20. Heinrich M, Barnes J, Gibbons S, Williamson M. Fundamentals of Pharmacognosy and Phytotherapy. Churchill Livingstone, London, 2004; p.161.
21. Berenbaum M.C. What is synergy? Pharmacol Rev 1989;41:93-141. [PubMed]
22. Williamson EM. Synergy in relation to the pharmacological action of phytomedicinals. In: Trease and Evans Pharmacognosy, Ed. Evans W.C., and Saunders W.B., Edinburgh, UK, 2002; pp. 49-54.
Thank you for visiting American Journal of BioMedicine. * = Required fields
